OTCPK:LVCL.Y

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Living Cell Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LVCL.Y's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

LVCL.Y

0.7%

US Biotechs

1.0%

US Market


1 Year Return

-58.0%

LVCL.Y

23.6%

US Biotechs

4.1%

US Market

Return vs Industry: LVCL.Y underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: LVCL.Y underperformed the US Market which returned 3.7% over the past year.


Shareholder returns

LVCL.YIndustryMarket
7 Day0%0.7%1.0%
30 Day-11.1%4.5%5.4%
90 Day-27.3%11.4%-5.7%
1 Year-58.0%-58.0%24.8%23.6%6.5%4.1%
3 Year-91.2%-91.2%35.4%30.9%28.3%19.8%
5 Year-82.6%-82.6%-2.3%-8.2%52.2%35.0%

Price Volatility Vs. Market

How volatile is Living Cell Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Living Cell Technologies undervalued compared to its fair value and its price relative to the market?

1.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LVCL.Y's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LVCL.Y's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LVCL.Y is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: LVCL.Y is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LVCL.Y's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LVCL.Y is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Living Cell Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

31.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Living Cell Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Living Cell Technologies performed over the past 5 years?

31.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LVCL.Y is currently unprofitable.

Growing Profit Margin: LVCL.Y is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LVCL.Y is unprofitable, but has reduced losses over the past 5 years at a rate of 31.3% per year.

Accelerating Growth: Unable to compare LVCL.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LVCL.Y is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: LVCL.Y has a negative Return on Equity (-46.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Living Cell Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: LVCL.Y's short term assets (A$4.1M) exceed its short term liabilities (A$419.5K).

Long Term Liabilities: LVCL.Y's short term assets (A$4.1M) exceed its long term liabilities (A$225.1K).


Debt to Equity History and Analysis

Debt Level: LVCL.Y is debt free.

Reducing Debt: LVCL.Y has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LVCL.Y has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LVCL.Y has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 14.9% each year.


Next Steps

Dividend

What is Living Cell Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LVCL.Y's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LVCL.Y's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LVCL.Y's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LVCL.Y's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LVCL.Y's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Ken Taylor (76yo)

5.83yrs

Tenure

AU$390,139

Compensation

Dr. Kenneth Taylor, also known as Ken, Ph.D. has been Chief Executive Officer of Living Cell Technologies Limited since July 1, 2014 and has been its Executive Director since August 31, 2018. Dr. Taylor se ...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD255.38K) is below average for companies of similar size in the US market ($USD595.62K).

Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Taylor
CEO & Executive Director5.83yrsAU$390.14kno data
Robert Elliott
Co-Founder & Director16.33yrsAU$77.90k0.90% A$43.5k
Daya Uka
Chief Financial Officer1.17yrsAU$150.95kno data
Janice Lam
Chief Operating Officer1.17yrsno datano data
Mark Licciardo
Company Secretary4.33yrsno datano data

2.8yrs

Average Tenure

76yo

Average Age

Experienced Management: LVCL.Y's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kenneth Taylor
CEO & Executive Director5.83yrsAU$390.14kno data
Robert Elliott
Co-Founder & Director16.33yrsAU$77.90k0.90% A$43.5k
Robert Moyse Willcocks
Independent Director9.17yrsAU$77.90kno data
Bernard Tuch
Independent Interim Chairman1.75yrsAU$94.57k0.0065% A$313.3
Carolyn Sue
Independent Director1yrAU$6.25kno data
Andrew Kelly
Independent Director0.50yrno data0.0092% A$448.8

1.8yrs

Average Tenure

71yo

Average Age

Experienced Board: LVCL.Y's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Living Cell Technologies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Living Cell Technologies Limited
  • Ticker: LVCL.Y
  • Exchange: OTCPK
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$7.421m
  • Listing Market Cap: AU$4.857m
  • Shares outstanding: 570.82m
  • Website: https://www.lctglobal.com

Location

  • Living Cell Technologies Limited
  • 330 Collins Street
  • Level 7
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LCTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDSep 2004
LVCL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2004
LCTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDSep 2004
LHIDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2004
LVCL.YOTCPK (Pink Sheets LLC)SPON ADRUSUSDJul 2007

Biography

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company’s lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson’s disease. Living Cell Technologies Limited has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. The company was founded in 1987 and is based in Melbourne, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/26 03:01
End of Day Share Price2020/05/20 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.